Ankit kumar

A digital marketing professional specializing in SEO, content optimization, and off-page strategies. Focused on promoting research-driven insights and improving

[Ankit kumar @Ankitkumar20922]

How can pharma turn oncology claims into smarter decisions?

Explore how oncology analytics transforms claims and real-world data into patient, treatment, competitive, and market insights.

Read: https://t.co/asTRnPCo6r

#OncologyAnalytics #RealWorldData #HealthcareAnalytics

[Ankit kumar @Ankitkumar20922]

Here's how AI-driven EMA pipeline intelligence helps pharma and biotech teams monitor EU drug development, catch competitor moves early, and turn regulatory data into strategic advantage.

Read : https://t.co/Ii52xgcZLy

#PharmaIntelligence #EMAPipelineIntelligence #ApothiumAI

[Ankit kumar @Ankitkumar20922]

Real-world evidence is now driving how pharma teams track treatment patterns, map the patient journey, and win in oncology market intelligence.

Read: https://t.co/v4g8gYD7Fi

#OncologyAnalytics #RealWorldData #PharmaAnalytics #HealthcareAI #MarketIntelligence #Healthcare

[Ankit kumar @Ankitkumar20922]

If your competitive intelligence isn't continuous, you're already behind. See what leading CAR-T teams are doing differently.

🔗 https://t.co/pHRtikZ6hC

#CARTherapy #CompetitiveIntelligence #CellAndGeneTherapy #LifeSciences #Immunotherapy

[Ankit kumar @Ankitkumar20922]

AI-powered KOL profiling is changing how pharma finds them — faster, sharper, and backed by real data instead of guesswork.

See how it works.

🔗https://t.co/I2pv778f11

#KOLProfiling #PharmaAI #MedicalAffairs #HealthcareIntelligence #LifeSciences

[Ankit kumar @Ankitkumar20922]

Our latest case study explores how AI-driven healthcare expert intelligence helps Medical Affairs teams identify relevant KOLs, emerging voices, and topic-specific expertise.

Read the case study: https://t.co/0LRY0q9bS5

#ApothiumAI #MedicalAffairs #KOLIntelligence #Pharma

[Ankit kumar @Ankitkumar20922]

Our latest analysis explores how pharma companies track drug development and regulatory trends—and how AI-driven intelligence is changing pipeline analysis.

Read:
https://t.co/DyKsQNE3Nz
#FDA #Pharma #Biotech #DrugDevelopment #ClinicalTrials #RegulatoryAffairs #Pharma

[Ankit kumar @Ankitkumar20922]

Our latest guide explains how KOL identification, profiling, network analysis, and AI-powered KOL intelligence can support smarter pharma decisions.

Explore:
https://t.co/bxfPrbYpwJ

#KOLMapping #KOLIdentification #KOLEngagement #MedicalAffairs #SPERMarketResearch

[Ankit kumar @Ankitkumar20922]

Discover smarter KOL intelligence with KOL Atlas. AI-powered insights help pharma & medical affairs teams identify experts, analyze influence, and plan engagement.
Explore.

🔗 https://t.co/RnYIXj39d4

#KOLIntelligence #MedicalAffairs #Pharma #KOL #Healthcare #SperMarketResearch

[Ankit kumar @Ankitkumar20922]

Our latest KOL case study explores hypertension treatment, resistant hypertension, emerging therapies, combination therapy, and the growing role of digital health and AI.

Explore:
https://t.co/Qwx5UqletB

#Hypertension #Healthcare #Pharma #KOLInsights #SPERMarketResearch

[Ankit kumar @Ankitkumar20922]

AI shopping agents aren't coming—they're already here. By 2030, agentic commerce could influence nearly half of all online purchases.

Is your brand ready for the AI-driven buying journey?
🔗 https://t.co/oNLuboBG1z

#AIShoppingAgent #AgenticCommerce #Ecommerce2030 #AIinRetail

[Ankit kumar @Ankitkumar20922]

From fragmented data to faster decisions. 🧬
See how AI-driven clinical intelligence helps pharma teams monitor trials, identify risks, optimize resources, and strengthen portfolio strategy.
🔗 https://t.co/dR7b36I8Hw

#AIinHealthcare #ClinicalTrials #Pharma #Oncology

[Ankit kumar @Ankitkumar20922]

Our latest guest post explores what to evaluate in KOL Intelligence Software, from AI-powered KOL mapping and data quality to enterprise integration, pricing, governance, and ROI.

Read: https://t.co/b313vbN6vb

#Pharma #KOLIntelligence #MedicalAffairs

[Ankit kumar @Ankitkumar20922]

Is #OpenAI Losing Its AI Dominance?

ChatGPT remains the largest AI chatbot, but its market share has reportedly fallen from around 90% in 2023 to approximately 46% in 2026.

Read:
https://t.co/E8upowk2hU

#ChatGPT #AIMarket #GenerativeAI #AITrends #SPERMarketResearch

[Ankit kumar @Ankitkumar20922]

Discover how pharma and biotech teams can use KOL intelligence, network analysis, AI, and scientific data to identify the right experts and strengthen Medical Affairs engagement.

Read:
https://t.co/h0hqpvkEWy

#MedicalAffairs #KOLMapping #Pharma #HealthcareAI

[Ankit kumar @Ankitkumar20922]

Transdermal drug delivery is entering a new growth phase.

With microneedles, iontophoresis, connected devices, and advanced formulations reshaping the landscape, the market is projected to reach USD 136.7B by 2030.

Read: https://t.co/74vlnmbbqd

#Pharma #MedTech #ApothiumAI

[Ankit kumar @Ankitkumar20922]

Network analysis tells you who actually influences the field.

From co-authorship and clinical trials to research clusters and emerging experts, #KOLIdentification is becoming more data-driven in 2026.

Read: https://t.co/I9imGxdzPg

#MedicalAffairs #LifeSciences #DigitalHealth

[Ankit kumar @Ankitkumar20922]

Explore expert perspectives on evolving lipid-lowering therapies, personalized cardiovascular risk assessment, access challenges, and the growing role of AI in lipid management.

Read: https://t.co/kbYrcq6r1a

#SPERMarketResearch #KOL #CardiovascularResearch #LipidManagement

[Ankit kumar @Ankitkumar20922]

What is shaping the future of #msc ?

Our latest KOL study explores expert perspectives on treatment advances, high-efficacy DMTs, biomarkers, AI, digital health, and access challenges.

Read:
https://t.co/BCToWv15iA

#SPERMarketResearch #KOLAtlas #MultipleSclerosis #MedTech

[Ankit kumar @Ankitkumar20922]

An AI KOL Discovery Tool now scores scientific experts in real time — publications, trials, digital engagement, all in one KOL Intelligence Dashboard.

How it's changing MSL strategy in 2026 👇
https://t.co/v2iA7CQO3s

#MedicalAffairs #PharmaSaaS